| Date Filed | Type | Description |
| 08/24/2023 |
8-K
| Entry into a Material Definitive Agreement Interactive Data |
| 08/08/2023 |
8-K
| Quarterly results |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/20/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 06/30/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ... |
| 06/16/2023 |
4
| Meyers James R (Director) has filed a Form 4 on CytomX Therapeutics, Inc.|
Txns:
| Granted 25,000 options to buy
@ $1.57, valued at
$39.3k
|
|
| 06/16/2023 |
4
| Mohindru Mani (Director) has filed a Form 4 on CytomX Therapeutics, Inc.|
Txns:
| Granted 25,000 options to buy
@ $1.57, valued at
$39.3k
|
|
| 06/16/2023 |
4
| Young Matthew P. (Director) has filed a Form 4 on CytomX Therapeutics, Inc.|
Txns:
| Granted 25,000 options to buy
@ $1.57, valued at
$39.3k
|
|
| 06/16/2023 |
4
| Ashworth Alan (Director) has filed a Form 4 on CytomX Therapeutics, Inc.|
Txns:
| Granted 25,000 options to buy
@ $1.57, valued at
$39.3k
|
|
| 06/16/2023 |
4
| Gilbert Halley E (Director) has filed a Form 4 on CytomX Therapeutics, Inc.|
Txns:
| Granted 25,000 options to buy
@ $1.57, valued at
$39.3k
|
|
| 06/16/2023 |
4
| Jones Elaine V (Director) has filed a Form 4 on CytomX Therapeutics, Inc.|
Txns:
| Granted 25,000 options to buy
@ $1.57, valued at
$39.3k
|
|
| 05/23/2023 |
4
| McCarthy Sean A. (CEO) has filed a Form 4 on CytomX Therapeutics, Inc.|
Txns:
| Exercised 16,535 options to buy
@ $1.5749, valued at
$26k
|
|
| 05/09/2023 |
8-K
| Quarterly results |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/27/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/31/2023 |
4
| Jones Elaine V (Director) has filed a Form 4 on CytomX Therapeutics, Inc.|
Txns:
| Bought 5,000 shares
@ $1.55, valued at
$7.8k
|
|
| 03/29/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/29/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 03/27/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/27/2023 |
8-K
| Quarterly results |
| 03/27/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/27/2023 |
10-K/A
| Annual Report for the period ended December 31, 2021 [amend] |
| 03/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/20/2023 |
4
| ROWLAND LLOYD A (General Counsel) has filed a Form 4 on CytomX Therapeutics, Inc.|
Txns:
| Sold 2,037 shares
@ $1.979, valued at
$4k
|
|
| 03/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 02/24/2023 |
8-K
| Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review  ... |
| 02/14/2023 |
SC 13G/A
| TANG CAPITAL PARTNERS LP reports a 5.3% stake in CytomX Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
|